ArticleScientific reports2022
Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.Psychiatry research · 2025Pooled it
- Exploring the therapeutic potential of psychedelics in treating substance use disorders.Molecular psychiatry · 2025Review
- Health-related behavioral changes following the use of psychedelics in naturalistic settings.Preventive medicine reports · 2025Article
- The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.Psychopharmacology · 2025Article
- Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats.Molecular psychiatry · 2025Article
- Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.PloS one · 2025Article
- Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.Frontiers in psychiatry · 2025Article
- The contribution of psychotherapy in potential therapeutic effects of psychedelics for treatment of opioid use disorder.Current addiction reports · 2025Article
- Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats.bioRxiv : the preprint server for biology · 2024Article
- Does LSD confer lasting psychological resilience? an investigation of naturalistic users experiencing job loss.PloS one · 2024Article
- Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.European addiction research · 2024Review
- Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.Addiction (Abingdon, England) · 2023Article
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.Scientific reports · 2023Article
- μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.Frontiers in pharmacology · 2023Review
- Psychedelic therapy in the treatment of addiction: the past, present and future.Frontiers in psychiatry · 2023Review
- Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.Frontiers in psychiatry · 2023Article
- Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cocaine Use Disorder (CUD) is a significant public health problem associated with elevated morbidity and mortality within the United States. Current behavioral treatments have limited efficacy and there are currently no FDA approved pharmacological treatments for CUD. Classic psychedelics might be associated with lowered odds of substance misuse and may effectively treat various forms of addiction. Thus, the goal of this study is to assess protective associations that lifetime use of classic psychedelics may share with CUD within a nationally representative sample of the U.S. We used data from The National Survey on Drug Use and Health (NSDUH) (2015-2019) and conducted survey-weighted multivariable logistic regression to test whether each of four classic psychedelics (peyote, mescaline, psilocybin, LSD) conferred lowered odds of CUD and its related 11 sub-criteria. Participants were 214,505 adults in the NSDUH (2015-2019) aged 18 and older. Peyote conferred lowered odds of CUD, reducing the odds of CUD by over 50% (aOR: 0.47). All other substances (including other classic psychedelics) either shared no association to CUD or conferred increased odds of CUD. Furthermore, sensitivity analyses revealed peyote to confer sharply lowered odds of the majority (seven of 11) of CUD criteria as well (aOR range: 0.26-0.47). Peyote use is associated with lowered odds of CUD. Future inquiries into third variable factors (i.e., demographic/personality profiles of individuals who use peyote, motivational/contextual factors surrounding peyote use) that may underlie our observed associations may reveal protective factors that can inform treatment development for CUD. Additionally, future longitudinal studies can shed further light on whether there is a temporal link between peyote use and lowered odds of CUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.